{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:34:52Z","timestamp":1793360092057,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100025191","name":"Eisai Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04241-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:45Z","timestamp":1766125365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5892-8706","authenticated-orcid":false,"given":"Prashant","family":"Changoer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-6581","authenticated-orcid":false,"given":"Chunying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-4140","authenticated-orcid":false,"given":"Pepijn","family":"van Houten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"van Emst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-5369","authenticated-orcid":false,"given":"Janneke E. W.","family":"Walraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-487X","authenticated-orcid":false,"given":"Petronella B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-493X","authenticated-orcid":false,"given":"Martin","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-0460","authenticated-orcid":false,"given":"Romana T.","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4241_CR1","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F et al (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860","journal-title":"Cancer Manag Res"},{"issue":"7","key":"4241_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621\u2013630","journal-title":"N Engl J Med"},{"issue":"11","key":"4241_CR3","first-page":"R173","volume":"29","author":"MC Hofmann","year":"2022","unstructured":"Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY et al (2022) Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer 29(11):R173\u2013R190","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"4241_CR4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/mc.23625","volume":"62","author":"A Buttell","year":"2023","unstructured":"Buttell A, Qiu W (2023) The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog 62(12):1918\u20131934","journal-title":"Mol Carcinog"},{"issue":"3","key":"4241_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/cancers13030558","volume":"13","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G (2021) PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel) 13(3):558","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4241_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1677\/ERC-08-0036","volume":"15","author":"M Ryder","year":"2008","unstructured":"Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15(4):1069\u20131074","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"4241_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1089\/thy.2011.0452","volume":"22","author":"W Qing","year":"2012","unstructured":"Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC et al (2012) Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 22(9):905\u2013910","journal-title":"Thyroid"},{"issue":"1","key":"4241_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361","journal-title":"Immunity"},{"issue":"4","key":"4241_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW (2023) A timeline of tumour-associated macrophage biology. Nat Rev Cancer 23(4):238\u2013257","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4241_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2014.09.014","volume":"41","author":"M Chittezhath","year":"2014","unstructured":"Chittezhath M, Dhillon Manprit K, Lim Jyue Y, Laoui D, Shalova Irina N, Teo YL et al (2014) Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 41(5):815\u2013829","journal-title":"Immunity"},{"issue":"1","key":"4241_CR11","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41467-022-33907-4","volume":"13","author":"K Rabold","year":"2022","unstructured":"Rabold K, Zoodsma M, Grondman I, Kuijpers Y, Bremmers M, Jaeger M et al (2022) Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat Commun 13(1):6149","journal-title":"Nat Commun"},{"issue":"2","key":"4241_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/pharmaceutics15020412","volume":"15","author":"C Peng","year":"2023","unstructured":"Peng C, Rabold K, Netea MG, Jaeger M, Netea-Maier RT (2023) Influence of lenvatinib on the functional reprogramming of peripheral myeloid cells in the context of non-medullary thyroid carcinoma. Pharmaceutics 15(2):412","journal-title":"Pharmaceutics"},{"key":"4241_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137","journal-title":"Eur J Cancer"},{"issue":"15","key":"4241_CR14","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2217\/fon-2020-0877","volume":"17","author":"D Liu","year":"2021","unstructured":"Liu D, Liu L, Shen L, Kubota T, Suzuki T, Ikezawa H et al (2021) Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors. Future Oncol 17(15):1855\u20131863","journal-title":"Future Oncol"},{"issue":"6","key":"4241_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00280-015-2899-0","volume":"76","author":"S Nakamichi","year":"2015","unstructured":"Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y et al (2015) A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76(6):1153\u20131161","journal-title":"Cancer Chemother Pharmacol"},{"key":"4241_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2017.10.037","volume":"413","author":"RT Netea-Maier","year":"2018","unstructured":"Netea-Maier RT, Smit JWA, Netea MG (2018) Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship. Cancer Lett 413:102\u2013109","journal-title":"Cancer Lett"},{"issue":"12","key":"4241_CR17","doi-asserted-by":"publisher","first-page":"e1229725","DOI":"10.1080\/2162402X.2016.1229725","volume":"5","author":"RJ Arts","year":"2016","unstructured":"Arts RJ, Plantinga TS, Tuit S, Ulas T, Heinhuis B, Tesselaar M et al (2016) Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology 5(12):e1229725","journal-title":"Oncoimmunology"},{"key":"4241_CR18","doi-asserted-by":"publisher","first-page":"101891","DOI":"10.1016\/j.redox.2021.101891","volume":"42","author":"KB Kennel","year":"2021","unstructured":"Kennel KB, Greten FR (2021) Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biol 42:101891","journal-title":"Redox Biol"},{"key":"4241_CR19","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol 12:636568","journal-title":"Front Immunol"},{"issue":"22","key":"4241_CR20","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1002\/cam4.4312","volume":"10","author":"J Zhu","year":"2021","unstructured":"Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W et al (2021) The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 10(22):7977\u20137987","journal-title":"Cancer Med"},{"issue":"1","key":"4241_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","volume":"6","author":"AA Lalani","year":"2018","unstructured":"Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM et al (2018) Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6(1):5","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4241_CR22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/cancers13061426","volume":"13","author":"NK Yun","year":"2021","unstructured":"Yun NK, Rouhani SJ, Bestvina CM, Ritz EM, Gilmore BA, Tarhoni I et al (2021) Neutrophil-to-lymphocyte ratio is a predictive biomarker in patients with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitor (TKI) therapy. Cancers (Basel) 13(6):1426","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4241_CR23","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1038\/oncsis.2015.14","volume":"4","author":"RN Gacche","year":"2015","unstructured":"Gacche RN (2015) Compensatory angiogenesis and tumor refractoriness. Oncogenesis 4(6):e153","journal-title":"Oncogenesis"},{"issue":"22","key":"4241_CR24","doi-asserted-by":"publisher","first-page":"32617","DOI":"10.18632\/oncotarget.8958","volume":"7","author":"M Tian","year":"2016","unstructured":"Tian M, Chen L, Ma L, Wang D, Shao B, Wu J et al (2016) Expression and prognostic significance of CCL11\/CCR3 in glioblastoma. Oncotarget 7(22):32617\u201332627","journal-title":"Oncotarget"},{"issue":"1","key":"4241_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12885-019-5768-0","volume":"19","author":"E Gobin","year":"2019","unstructured":"Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N et al (2019) A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic\/prognostic potential. BMC Cancer 19(1):581","journal-title":"BMC Cancer"},{"issue":"11","key":"4241_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","volume":"19","author":"DW Stuckey","year":"2013","unstructured":"Stuckey DW, Shah K (2013) TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 19(11):685\u2013694","journal-title":"Trends Mol Med"},{"issue":"1","key":"4241_CR27","doi-asserted-by":"publisher","first-page":"e20190418","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Vieira P, O\u2019Garra A (2020) Biology and therapeutic potential of interleukin-10. J Exp Med 217(1):e20190418","journal-title":"J Exp Med"},{"issue":"7","key":"4241_CR28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/cancers12071791","volume":"12","author":"C R\u00e9b\u00e9","year":"2020","unstructured":"R\u00e9b\u00e9 C, Ghiringhelli F (2020) Interleukin-1\u03b2 and cancer. Cancers (Basel) 12(7):1791","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4241_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"key":"4241_CR30","first-page":"6178921","volume":"2016","author":"TP Kobawala","year":"2016","unstructured":"Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR (2016) Significance of interleukin-6 in papillary thyroid carcinoma. J Thyroid Res 2016:6178921","journal-title":"J Thyroid Res"},{"issue":"5","key":"4241_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen KC, Liu L-F, Gupta V, Madireddi S, Keerthivasan S, Li C et al (2020) High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med 26(5):693\u2013698","journal-title":"Nat Med"},{"key":"4241_CR32","doi-asserted-by":"publisher","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C (2021) Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther 219:107692","journal-title":"Pharmacol Ther"},{"issue":"12","key":"4241_CR33","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1177\/0300060518800588","volume":"46","author":"L Feng","year":"2018","unstructured":"Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z et al (2018) Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res 46(12):5228\u20135236","journal-title":"J Int Med Res"},{"issue":"1","key":"4241_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","volume":"281","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Barajon I, Garlanda C (2018) IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev 281(1):57\u201361","journal-title":"Immunol Rev"},{"issue":"4","key":"4241_CR35","doi-asserted-by":"publisher","first-page":"e12441","DOI":"10.1111\/cpr.12441","volume":"51","author":"J Shen","year":"2018","unstructured":"Shen J, Xiao Z, Zhao Q, Li M, Wu X, Zhang L et al (2018) Anti-cancer therapy with TNF\u03b1 and IFN\u03b3: a comprehensive review. Cell Prolif 51(4):e12441","journal-title":"Cell Prolif"},{"issue":"1","key":"4241_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12935-024-03418-x","volume":"24","author":"W Lin","year":"2024","unstructured":"Lin W, Wang X, Diao M, Wang Y, Zhao R, Chen J et al (2024) Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer. Cancer Cell Int 24(1):239","journal-title":"Cancer Cell Int"},{"issue":"7","key":"4241_CR37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S (2020) MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel) 12(7):1760","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4241_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, Li Y, Long KB (2017) Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther 17(2):175\u2013186","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"4241_CR39","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19(5):1035\u20131043","journal-title":"Clin Cancer Res"},{"issue":"17","key":"4241_CR40","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","volume":"30","author":"JD French","year":"2024","unstructured":"French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B et al (2024) Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res 30(17):3757\u20133767","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4241_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31(7):1076\u20131085","journal-title":"Thyroid"},{"issue":"14","key":"4241_CR42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300","journal-title":"N Engl J Med"},{"issue":"5","key":"4241_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386(5):437\u2013448","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04241-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:47Z","timestamp":1766170907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4241"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04241-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local Ethics Committee (Commissie Mensgebonden Onderzoek Arnhem-Nijmegen: 2020-7123 for longitudinal patients, 2022-16025 for cross-sectional patients, NL84281.091.23 for healthy donors). All donors provided written informed consent, and all study procedures were conducted according to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"14"}}